Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012		Mar. 31, 2013 Cytochroma acquisition [Member]		Mar. 31, 2013 Cytochroma acquisition [Member] Patents [Member]	Mar. 31, 2013 Cytochroma acquisition [Member] In Process Research and Development [Member]	Aug. 29, 2013 PROLOR [Member]		Aug. 29, 2013 PROLOR [Member] Patents [Member]	Aug. 29, 2013 PROLOR [Member] In Process Research and Development [Member]
Business Acquisition [Line Items]
Current assets					$ 1,224,000	[1]			$ 21,500,000	[1]
Intangible assets:
In-process research and development								191,530,000				590,200,000
Patents							210,000				0
Total intangible assets					191,740,000				590,200,000
Goodwill	222,340,000	[2]	80,450,000	[2]	2,411,000				139,784,000
Property, plant and equipment					306,000				1,057,000
Other assets					0				371,000
Accounts payable and accrued expenses					(1,069,000)				(9,866,000)
Business Acquisition, Purchase Price Allocation, Deferred Taxes Asset (Liability), Net, Noncurrent					0				(156,403,000)
Total purchase price					194,612,000				586,643,000
Current Asset include cash					$ 400,000				$ 20,500,000

[1] Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively

[2] As of September 30, 2013 and December 31, 2012, total assets include $5.9 million and $5.6 million, respectively, and total liabilities include $8.7 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.